Analysis of outcome of Stage 1-111 endometrial cancer treated with systematic operation omitting paraaortic lymphadenectomy

Purpose: The aim of this study was to assess the outcomes of endometrial cancer patients treated with systematic surgery omitting paraarotic lymphadenectomy.

Patients and methods: We retrospectively analyzed a consecutive series of 84 endometrioid-type endometrial cancer patients at FIGO Stage I, II or III without grossly metastatic paraaortic lymphadenodes, who underwent surgery at our institute.

Results: Sixty-five patients (77%) underwent primary surgery with pelvic lymphadenectomy while the remaining 19 patients underwent surgery without lymphadenectomy due to severe medical complications or age greater than 70 years. The patients with high risk for recurrence were treated mainly by adjuvant irradiation therapy of the whole pelvis. The median follow-up period was 44 months. The 5-year overall survival (OS) rate was 92%, 92% and 65% for FIGO Stage I, II and III, respectively. Recurrence was detected in eight of the 82 optimally operated patients (9.8%). Out of the eight recurrent patients, five patients had a recurrent tumor at extra-pelvic sites (chest or abdomen), two patients had a recurrent tumor only in a paraaortic lymph node, and one patient had a recurrent tumor only in the vagina. Thus, the recurrence rate was relatively low, with 2.4% relapse at the paraarotic lymph nodes, and 5-year OS rate appeared to be favorable. However, all the six recurrent patients who underwent adjuvant radiation therapy had distant recurrence.

Conclusions: These findings indicate that omission of paraarotic lymphadenectomy may be acceptable for endometrial cancer patients without gross metastasis at this site. However, the high rate of distant recurrence after whole pelvic irradiation strongly indicates an urgent need to develop potent systemic adjuvant therapy, potentially by chemotherapy or chemoradiation therapy.

Endometrial cancer; Operation; Paraaortic lymphadenectomy; Recurrence; Prognosis

[1] Disaia P.J., Creasman W.T., Boronow R.C., Blessing J.A.: "Risk factors and recurrent patterns in Stage I endometrial cancer". Am J. Obstet. Gynecol., 1985, 15, 151, 1009.

[2] Lurain J.R.. Rice B.L., Rademaker A.W., Poggensee L.E., Schink J.C.. Miller D.S.: "Prognostic factors associated with recurrence in clinical Stage I adenocarcinoma of the endometrium". Obstet Gynecol., 1991, 78, 63.

[3] Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D., Graham J.E.: "Relationship between surgicalpathological risk factors and outcome in clinical Stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study". Gynecol. Oncol., 1991, 40, 55.

[4] Creasman W.: "New gynecologic cancer staging". Obstet Gynecol., 1990, 75, 187.

[5] Blythe J.G., Edwards E., Heimbecker P.: "Paraaortic lymph node biopsy: a twenty-year study". Am. J. Obstet. Gynecol., 1997, 176, 1157.

[6] Chuang L.. Burke T.W., Tornos C., Marino B.D., Mitchell M.F.. Tortolero-Luna G. et al.: "Staging laparotomy for endometrial carcinoma: assessment of retroperitoneal lymph nodes". Gynecol Oneal., 1995, 58. 189.

[7] Creutzberg C.L.. van Putten W.L.. Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C. et al.: "Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma". Lancet, 2000, 355, 1404.

[8] Kilgore L.C., Partridge E.E., Alvarez R.D., Austin J.M., Shingleton H.M., Noojin F. 3,d, Conner W.: "Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling". Gynecol. Oneal., 1995, 56, 29.

[9] Otsuka I., Kubota T., Aso T.: "Lymphadenectomy and adjuvant therapy in endometrial carcinoma: role of adjuvant chemotherapy". Br. J. Cancer, 2002, 87, 377.

[10] Kim Y.B., Niloff J.M.: "Endometrial carcinoma: analysis of recurrence in patients treated with a strategy minimizing lymph node sampling and radiation therapy". Obstet. Cynecol., 1993, 82, 175.

[11] Straughn J.M.. Huh W.K., Orr J.W. Jr, Kelly F.J., Roland P.Y., Gold M.A. et al.: "Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy". Cynecol. Oneal., 2003, 89, 295.

[12] Ayhan A., Taskiran C., Celik C., Yuce K.:''The long-term survival of women with surgical Stage II endometrioid type endometrial cancer". Gynecol. Oneal., 2004, 93, 9.

[13] Katz L.A., Andrews S.J., Fanning J.: "Survival after multimodality treatment for Stage IllC endometrial cancer". Am. J. Obstet. Gynecol., 2001, 184, 1071.

[14] Ayhan A., Taskiran C., Celik C., Aksu T., Yuce K.: "Surgical stage III endometrial cancer: analysis of treatment outcomes. prognostic factors and failure patterns". Eur. J. Gynaecol. Oneal., 2002, 23, 553.

[15] Schorge J.O., Molpus K.L., Goodman A., Nikrui N., Fuller A.F Jr.: "The effect of postsurgical therapy on Stage III endometrial carcinoma". Gynecol. Oneal., 1996, 63, 34.

[16] Faught W., Krepart G.V., Lotocki R., Heywood M.: "Should selective paraaortic lymphadenectomy be part of surgical staging for endometrial cancer?". Gynecol. Oneal., 1994. 55, 51.

[17] Hirahatake K., Hareyama H., Sakuragi N., Nishiya M., Makinoda S., Fujimoto S.: "A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma". J. Surg. Oncol., 1997, 65, 82.

[18] Bristow R.E., Zahurak M.L., Alexander CJ., Zellars R.C., Montz F.J.: "FIGO Stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival" Int. J. Gynecol. Cancer, 2003, 13, 664.

[19] Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Manne! R.S., Fowler J. et al., Gynecologic Oncology Group Study: "Randomized phase Ill trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study". J. Clin. Oneal., 2006, 24, 36.

[20] Sagae S., Udagawa Y., Susumu K., Niwa R., Kudo R., Nozawa S JGOG2033: "Randomized phase Ill trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with interme diate risk endometrial carcinoma". ASCO Abst. No. 5002, 2005.

[21] Onda T., Yoshikawa H., Mizutani K., Mishma M., Yokota H.. Nagano H. et al.: "Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy". Br. J. Cancer, 1997, 75, 1836.